In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 2, 2000, Pages 239-242

  Rodero, L ^a   Cordoba S ^a   Cahn, P ^b   Hochenfellner, F ^a   Davel, G ^a   Canteros, C ^a   Kaufman, S ^b   Guelfand, L ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^b HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; RIFAMPICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CRYPTOCOCCUS NEOFORMANS; FUNGAL MENINGITIS; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; HUMAN; TIME;

EID: 0343384314     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.2.239     Document Type: Article

References (11)

1. Mitchell, T. G. & Perfect, J. R. (1995). Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clinical Microbiology Reviews 8, 515-48.
2. Cahn, P., Cuatz, D., Guelfand, L., Kaufman, S. & Perez, H. (1995). Cryptococcal meningitis is a frequent first AIDS-defining illness with high rates of relapse in Argentina. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 1990, Abstract 1-98, p. 222. American Society for Microbiology, Washington, DC.
3. Van der Horst, C., Saag, M. S., Cloud, G. A., Hamill, R. A., Graybill, J. R., Sobel, J. D. et al. (1997). Treatment of cryptococcal meningitis associated with immunodeficiency syndrome. New England Journal of Medicine 337, 15-21.
4. Mayanja-Kizza, H., Oishi, K., Mitarai, S., Yamashita, H., Nalongo, K., Watanabe, K. et al. (1998). Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clinical Infectious Diseases 26, 1362-6.
5. Bennett, J. E., Dismukes, W. E., Duma, R. J., Medoff, G., Sande, M. A., Gallis, H. et al. (1979). A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. New England Journal of Medicine 301, 126-31.
6. Denning, D. W., Hanson, L. H., Perlman, A. M. & Stevens, D. A. (1992). In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagnosis in Microbiology and Infectious Diseases 15, 21-34.
7. Edwards, J. E., Jr, Morrison, J., Henderson, D. K. & Montgomerie, J. Z. (1980). Combined effect of amphotericin B and rifampin on Candida species. Antimicrobial Agents and Chemotherapy 17, 484-7.
8. Rodero, L., Córdoba, S., Guelfand, L., Kaufman, S., Hochenfellner, F., Rossi, A. et al. (1996). In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with AIDS. In Program and Abstracts of the Third International Conference of Cryptococcus and Cryptococcosis, Institut Pasteur, Paris, 1996. Abstract 3.2, p. 175. International Society for Human and Animal Mycology, The Netherlands.
9. Powderly, W. G. (1992). Therapy for cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases 14, Suppl. 1, S54-9.
10. Nguyen, M. H., Barchiesi, F., McGough, D., Yu, V. L. & Rinaldi, M. G. (1995). In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrobial Agents and Chemotherapy 39, 1691-5.
11. Johnson, C. C. (1996). In vitro testing: correlation between bactericidal susceptibility, body fluid levels and effectiveness of antibacterial therapy. In Antibiotics in Laboratory Medicine, 4th edn (Lorian, V., Ed.), pp. 813-34. Williams & Wilkins, Baltimore, MD.